Sonnet BioTherapeutics continues to Climb following Janssen Announcement

(24/7 MARKET NEWS) – We reported, yesterday, that Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) announced that its three products, SON-1010, SON-1210 and SON-1410 will be evaluated in combination with Johnson & Johnson’s Janssen Pharmaceutical, of Johnson & Johnson.

Sonnet opened yesterday at $1.38, traded as high as $2.70, and closed at $1.93, 77 cents higher (+66.38%), on volume of 102,368,460 shares.

Sonnet opened at $1.98 and is now at $2.68, up $0.75 (+38.86%), on 37,867,997 shares. It’s traded as high as $3.00 and, although that looked like an anomaly, that’s now the next key inflection point.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist